Skip to content

Carbohydrate Intake and Gut Hormone Release During Exercise

Carbohydrate Intake and Gut Hormone Release During Exercise

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04019418
Enrollment
12
Registered
2019-07-15
Start date
2019-02-21
Completion date
2020-02-12
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

carbohydrate, exercise, PYY, GLP-1, ghrelin, hormones

Brief summary

It is well known that following a single session of moderate-to-high intensity exercise individuals experience a temporary suppression of hunger and a delay in the commencement of eating. This effect is believed to be due to changes in blood concentrations of specific hormones released from the gut that influence appetite. Individuals undertaking physical activity often consume foods immediately before exercise in order to improve their performance. However, it is currently unknown whether this eating practice influences the gut hormone response to exercise as well as how hungry an individual feels post-exercise. Therefore, the aim of this study is to investigate the effect of consuming a sugary (carbohydrate) drink immediately before starting an exercise session on the concentration of these gut hormones as well as the amount of food eaten in the hours following exercise completion.

Detailed description

It is well established that following an acute bout of moderate-to-high intensity exercise individuals experience a transient suppression of hunger and a delay in the commencement of eating - a phenomenon referred to as exercise-induced anorexia. Acute exercise modulates the concentrations of gut hormones known to influence satiety, including the anorexigenic hormones glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine (PYY), as well as the acylated form of the orexigenic hormone ghrelin. These alterations in gut hormone concentrations have consequently been hypothesised to play a key role in exercise-induced anorexia. Despite suppressing hunger and delaying eating, acute exercise does not appear to alter short-term energy intake in the immediate hours following exercise completion. The absence of a compensatory response therefore creates an energy deficit capable of inducing weight loss. Strategies that augment the gut hormone response to acute exercise may thus increase the potency of exercise as a weight-loss tool. Research investigating the effect of exercise on appetite has frequently utilised participants in a fasting state. Undertaking exercise in this physiological condition contradicts current practices, as athletes often consume a carbohydrate source immediately prior to exercise in an attempt to maximise performance. It is currently unknown as to whether the consumption of carbohydrate during this period may further enhance the gut hormone response to exercise, and thus research into a potential additive effect is warranted. High-intensity exercise increases sympathetic nervous system activity and catecholamine release. Catecholamine concentrations are negatively correlated with acylated ghrelin concentrations and may directly stimulate GLP-1 and PYY release via activation of β-receptors located on L-cells. The decrease in gastric emptying rate that is observed during high-intensity exercise is also attributed to this increase in sympathetic activity. Consequently, an increase in sympathetic nervous system activity has been postulated as a key mechanism underlying exercise-induced changes in gut hormone concentrations. However, to our knowledge, no study has directly measured the relationship between sympathetic nervous system activity and anorexigenic gut hormone release during exercise. Therefore, the aim of this study is to examine any potential additive effects of carbohydrate ingestion immediately prior to exercise on gut hormone release and post-exercise appetite suppression. Furthermore, this study will look to investigate the mechanisms underlying changes in gut hormone concentrations experienced during exercise.

Interventions

DIETARY_SUPPLEMENTMaltodextrin (carbohydrate)

A drink containing 300ml of water and 75g of maltodextrin

OTHERExercise

30 minutes on a cycle ergometer working at 75% VO2 max

OTHERRest

30 minutes laying on a bed

OTHERWater

A drink containing 300ml of water

Sponsors

Imperial College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Participants and investigators will be masked to the contents of the beverage. They will not be masked to whether it is a resting or exercise condition as this is not possible.

Intervention model description

Participants perform all four trials in a randomized order

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Male * Age between 18-40 years (inclusive) * Body mass index (BMI) of 18-30 kg/m2 * Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements

Exclusion criteria

* Abnormal ECG * Screening blood results outside of normal reference values * Current smokers * Current or history of substance abuse and/or excess alcohol intake * Diabetes * Cardiovascular disease * Cancer * Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome * Kidney disease * Liver disease * Pancreatitis * Started new medication within the last 3 months likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones. * Participation in a research study in the 12 week period prior to entering this study. * Any blood donation within the 12 week period prior to entering this study

Design outcomes

Primary

MeasureTime frameDescription
Changes in GLP-1 concentrationDuring the study visit, 165 minutesChanges in GLP-1 concentration between exercise and resting conditions, and between carbohydrate and control conditions
Changes in PYY concentrationDuring the study visit, 165 minutesChanges in PYY concentration between exercise and resting conditions, and between carbohydrate and control conditions
Changes in acylated ghrelin concentrationDuring the study visit, 165 minutesChanges in acylated ghrelin concentration between exercise and resting conditions, and between carbohydrate and control conditions

Secondary

MeasureTime frameDescription
Changes in energy balanceDuring the study visit, 165 minutesDifferences in energy balance between exercise and resting conditions, and between carbohydrate and control conditions.
Changes in subjective appetiteDuring the study visit, 165 minutesChanges in subjective feelings of appetite as measured by visual analogue scales between exercise and resting conditions, and between carbohydrate and control conditions. Visual analogue scales will range from 0 mm to 100 mm with a higher score indicating a higher degree of fullness.
Changes in subjective nauseaDuring the study visit, 165 minutesChanges in subjective feelings of nausea as measured by visual analogue scales between exercise and resting conditions, and between carbohydrate and control conditions. Visual analogue scales will range from 0 mm to 100 mm with a higher score indicating a higher degree of nausea.
Glucose homeostasisDuring the study visit, 165 minutesChanges in glucose homeostasis between exercise and resting conditions, and between carbohydrate and control conditions.
Changes in energy intakeDuring the study visit, 165 minutesDifferences in energy intake at an ad libitum meal between exercise and resting conditions, and between carbohydrate and control conditions
Changes in Energy expenditureDuring the study visit, 165 minutesDifferences in energy expenditure between exercise and resting conditions, and between carbohydrate and control conditions.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026